## CITATION REPORT List of articles citing

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis

DOI: 10.1016/j.crohns.2013.01.014
Journal of Crohn**p** and Colitis, 2013, 7, 853-67.

**Source:** https://exaly.com/paper-pdf/55615934/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
155	The risk of postoperative complications following preoperative anti-TNF therapy in patients with Crohn's disease: the need for prospective studies. <i>Journal of Crohnmand Colitis</i> , <b>2013</b> , 7, e493-4	1.5	
154	Review article: optimal preparation for surgery in Crohn's disease. <b>2014</b> , 40, 1009-22		45
153	Positioning therapy for Crohn's disease. <b>2014</b> , 16, 384		
152	Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. <b>2014</b> , 12, 224-30		102
151	PRISMAefficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. <b>2014</b> , 93, e326		52
150	Clinical Practice Guideline for the Surgical Management of Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , <b>2015</b> , 58, 1021-36	3.1	78
149	Anti-Tumor Necrosis Factor-Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 2658-	72 <sup>4.5</sup>	33
148	A review of the impact of biologics on surgical complications in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1472-7	4.5	16
147	Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. <b>2015</b> , 149, 928-37		67
146	Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review. <b>2015</b> , 35, 128-13	36	2
145	Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era". <i>Journal of Gastrointestinal Surgery</i> , <b>2015</b> , 19, 1842-51	3.3	11
144	Predictors and risks for death in a population-based study of persons with IBD in Manitoba. <b>2015</b> , 64, 1403-11		48
143	Comparison of Estimates between Cohort and Case-Control Studies in Meta-Analyses of Therapeutic Interventions: A Meta-Epidemiological Study. <b>2016</b> , 11, e0154877		4
142	NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-Inhibitors. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2016</b> , 63, 130-55	2.8	17
141	Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. <i>Journal of Crohnmand Colitis</i> , <b>2017</b> , 11, 671-679	1.5	11
140	Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 2602-7	4	9
139	Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. <b>2016</b> , 44, 807-16		78

138	Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease?. <i>Journal of Gastrointestinal Surgery</i> , <b>2016</b> , 20, 1867-1873	3.3	10
137	Patient optimization for surgery relating to Crohn's disease. <b>2016</b> , 13, 707-719		52
136	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. <b>2016</b> , 4, 784-793		52
135	Chronisch-entzBdliche Darmerkrankungen. <b>2016</b> , 38, 314-325		2
134	A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. <i>Journal of Crohnmand Colitis</i> , <b>2016</b> , 10, 773-8	1.5	43
133	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 338-	358	34
132	Withdrawal of drug therapy for patients with quiescent Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b>	5.2	О
131	As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection. <i>Journal of Gastrointestinal Surgery</i> , <b>2017</b> , 21, 1159-1165	3.3	16
130	Surgical Management of Crohn® Disease and Ulcerative Colitis. 2017, 505-517		
129	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <b>2017</b> , 46, 3-15		82
128	Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis. <i>International Journal of Colorectal Disease</i> , <b>2017</b> , 32, 1215-1222	3	15
127	Management and Prevention of Infectious Diseases in IBD Patients. <b>2017</b> , 621-638		
126	Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 456-464	4	46
125	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <b>2017</b> , 112, 337-345		104
124	Ileocecal Resection in Crohn's Disease: REMIND Group Study. <b>2017</b> , 112, 1479		
123	Response to Dhoble et al. <b>2017</b> , 112, 1479-1480		1
122	Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. <b>2017</b> , 5, 554-5	62	17
121	Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. <b>2017</b> , 112, 1423-1429		70

120 Impact des traitements de la maladie de Crohn sur la morbidit©hirurgicale. 2017, 11, 140-146

119	Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. <b>2017</b> , 104, 1713-1722		58
118	Surgical care of the pediatric Crohn's disease patient. <b>2017</b> , 26, 373-378		6
117	Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease. <i>Journal of Crohnmand Colitis</i> , <b>2017</b> , 11, 185-190	1.5	101
116	The Cutting Edge of Intestinal Surgery for Crohn's Disease: a Multidisciplinary Team Approach. <b>2017</b> , 70, 611-622		1
115	Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 871-876	4.5	44
114	The cholinergic anti-inflammatory pathway revisited. <b>2018</b> , 30, e13288		24
113	Is Anti-TNF Therapy Associated With an Increased Risk of Postoperative Morbidity After Surgery for Ileocolonic Crohn Disease?. <b>2018</b> , 267, 229-230		
112	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-hagents). <b>2018</b> , 24 Suppl 2, S10-S20		94
111	Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 713-722	4	7
110	Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-Antagonists. <b>2018</b> , 52, 571-579		8
109	Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. <b>2018</b> , 47, 573-580		46
108	[Perioperative handling of immunosuppressive therapy]. <b>2018</b> , 89, 116-121		3
107	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease. <i>Journal of Crohnmand Colitis</i> , <b>2018</b> , 12, 402-407	1.5	48
106	Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 422-432	4.5	19
105	Anti-TNF Therapy Is Associated With an Increased Risk of Postoperative Morbidity After Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort. <b>2018</b> , 267, 221-228		81
104	Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. <b>2018</b> , 53, 1706-1709		19
103	Intra-abdominal Sepsis After Ileocolic Resection in Crohn's Disease: The Role of Combination Immunosuppression. <i>Diseases of the Colon and Rectum</i> , <b>2018</b> , 61, 1393-1402	3.1	18

102	ANALYSIS OF RISK FACTORS AND POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH CROHN'S DISEASE. <b>2018</b> , 55, 252-257		7
101	Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease. <i>Techniques in Coloproctology</i> , <b>2018</b> , 22, 947-953	2.9	7
100	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <b>2018</b> , 1, 115-1	23	21
99	Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study. <i>Journal of Crohnmand Colitis</i> , <b>2018</b> , 12, 1392-1398	1.5	9
98	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology and Nutrition,	2.8	145
97	2018, 67, 257-291 Recent trends (2016-2017) in the treatment of inflammatory bowel disease. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 282-288	4.3	19
96	Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. <i>The Cochrane Library</i> , <b>2018</b> , 5, CD012540	5.2	16
95	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818783614	4.7	8
94	Visceral fat area measured with computed tomography does not predict postoperative course in Crohn[s disease patients. <b>2018</b> , 13, e0202220		4
93	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 472-478	4.5	
92	Neuroimmune Communication in Health and Disease. <b>2018</b> , 98, 2287-2316		47
91	Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. <b>2018</b> , 48, 340-346		15
90	Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 261-269	4.5	23
89	Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study. <b>2019</b> , 10, e00050		12
88	Current Status of Segmental Colectomy in Select Crohn's Disease Patients. <b>2019</b> , 32, 249-254		2
87	SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE. <b>2019</b> , 30, 349-35	56	
86	Gestion plioplatoire des biothlapies en 2019. <b>2019</b> , 5, 274-284		1
85	Postoperative Considerations in Inflammatory Bowel Disease. <b>2019</b> , 99, 1095-1109		

84	Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?. <b>2019</b> , 50, 969-970	1
83	Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. <b>2019</b> , 1,	3
82	Anti-TNF Use Prior to Bowel Resection Is Not Associated With 30 Day Postoperative Complications: A National Database Study. <b>2019</b> , 1,	2
81	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn Disease: Single-Center Series. <b>2019</b> , 1,	4
80	Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. <b>2019</b> , 7, 1198-1214	5
79	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <b>2019</b> , 68, s1-s106	557
78	Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1959-1966	6
77	Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. <b>2019</b> , 54, 2162-2165	3
76	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <b>2019</b> , 21, 1279-1287	4
75	Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. <b>2019</b> , 7, 168-175	10
74	Managing Biologics Perioperatively. <b>2019</b> , 59-71	
73	Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database. <i>Journal of Gastrointestinal Surgery</i> , <b>2019</b> , 23, 1188 <sup>2</sup> १७१	7 <sup>6</sup>
72	Surgery in the age of biologics. <b>2019</b> , 7, 77-90	32
71	Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1613-1620  4.5	2
70	The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1559-1568	7
69	Surgery and paediatric inflammatory bowel disease. <b>2019</b> , 8, 436-448	1
68	Preoperative Considerations in Inflammatory Bowel Disease. <b>2019</b> , 99, 1083-1094	2
67	Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?. <i>Diseases of the Colon and Rectum</i> , <b>2019</b> , 62, 1352-1362	14

66	ACG Clinical Guideline: Ulcerative Colitis in Adults. 2019, 114, 384-413		458
65	The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2019</b> , 68, 334-338	2.8	8
64	Preoperative Enteral Nutrition and Surgical Outcomes in Adults with Crohn's Disease: A Systematic Review. <b>2019</b> , 26, 184-195		8
63	Systematic review of perioperative use of immunosuppressive agents in patients undergoing bariatric surgery. <b>2020</b> , 16, 144-157		1
62	Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 501-512	3	2
61	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohnmand Colitis</i> , <b>2020</b> , 14, 155-168	1.5	122
60	Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis. <i>Journal of Gastrointestinal Surgery</i> , <b>2020</b> , 24, 2637-2642	3.3	1
59	Use of Biological Medications Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Colectomy: A Retrospective Cohort Analysis of Privately Insured Patients. <i>Diseases of the Colon and Rectum</i> , <b>2020</b> , 63, 1524-1533	3.1	1
58	Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1796-1807	4.5	5
57	Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. <b>2020</b> , 10, e038429		
56	Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820931738	4.7	7
55	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD013256	5.2	2
54	The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 175	62 <del>8</del> 482	20937089
53	Postoperative complications in Crohn disease. 2020, 235-248		
52	Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 485	8.4	3
51	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. <i>Techniques in Coloproctology</i> , <b>2020</b> , 24, 397-419	2.9	16
50	Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients. <i>Diseases of the Colon and Rectum</i> , <b>2020</b> , 63, 934-943	3.1	3
49	Modern surgery for ulcerative colitis. <i>Updates in Surgery</i> , <b>2020</b> , 72, 325-333	2.9	3

48	Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 727-737	3	4
47	Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases. <i>Annals of Gastroenterological Surgery</i> , <b>2020</b> , 4, 30-38	4.3	8
46	Surgery for Inflammatory Bowel Disease in the Era of Biologics. <i>Journal of Gastrointestinal Surgery</i> , <b>2020</b> , 24, 1430-1435	3.3	4
45	Postoperative mortality after surgery for inflammatory bowel disease: The myth of Apollo and Artemis. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 52-53	3.3	
44	Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern Europe. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 54-60	3.3	2
43	Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
42	Non-invasive peripheral focused ultrasound neuromodulation of the celiac plexus ameliorates symptoms in a rat model of inflammatory bowel disease. <i>Experimental Physiology</i> , <b>2021</b> , 106, 1038-1060	) <sup>2.4</sup>	1
41	Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	1
40	Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD. <i>Southern Medical Journal</i> , <b>2021</b> , 114, 98-105	0.6	3
39	Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1433-1442	3.7	2
38	Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease-An International Survey of Practice. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2021</b> , 73, 54-60	2.8	2
37	The Pathogenesis and Clinical Management of Stricturing Crohn Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1839-1852	4.5	1
36	Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery. Digestive Diseases and Sciences, <b>2021</b> , 1	4	
35	A retrospective comparison of outcomes for open laparoscopic surgical techniques in pediatric ulcerative colitis. <i>Translational Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 41	5.2	O
34	Continued Postoperative Use of Tumor Necrosis Factor—Inhibitors for the Prevention of Crohn's Disease Recurrence. <i>Gut and Liver</i> , <b>2021</b> ,	4.8	
33	Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. <i>Frontiers in Pediatrics</i> , <b>2021</b> , 9, 708310	3.4	O
32	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
31	Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> ,	3	3

## (2022-2021)

30	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Archiv Fur Pathologische Anatomie	5.1	8
29	Und Physiologie Und Fur Klinische Medizin, 2021, 478, 581-594. Concepts in Inflammatory Bowel Disease Management. 2019, 1888-1918		1
28	Pre-operative optimisation in Crohn's Disease. Seminars in Colon and Rectal Surgery, 2020, 31, 100742	0.3	2
27	Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 799-816	2.2	3
26	Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , <b>2019</b> , 20, 1317-1322	3	6
25	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. <i>Current Drug Targets</i> , <b>2019</b> , 20, 1339-1348	3	7
24	Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?. <i>Current Drug Targets</i> , <b>2019</b> , 20, 1369-1372	3	5
23	CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). <i>Koloproktologia</i> , <b>2020</b> , 19, 8-38	0.8	34
22	Surgery for luminal Crohn's disease. World Journal of Gastroenterology, 2014, 20, 78-90	5.6	56
21	Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. <i>Intestinal Research</i> , <b>2017</b> , 15, 160-165	4.1	9
20	Human Embryonic Stem Cell Therapy in Crohn's Disease: A Case Report. <i>American Journal of Case Reports</i> , <b>2016</b> , 17, 124-8	1.3	2
19	Morbus Crohn ©olitis ulcerosa. <b>2017</b> , 103-119		
18	Correlation between age of onset and gastrointestinal stenosis in hospitalized patients with Crohn's disease. <i>World Journal of Clinical Cases</i> , <b>2020</b> , 8, 2769-2777	1.6	
17	Synergistic effect of combined melatonin and adipose-derived mesenchymal stem cell (ADMSC)-derived exosomes on amelioration of dextran sulfate sodium (DSS)-induced acute colitis. <i>American Journal of Translational Research (discontinued)</i> , <b>2019</b> , 11, 2706-2724	3	11
16	Preoperative Evaluation and Management of Patients Receiving Biologic Therapies. <i>Archives of Bone and Joint Surgery</i> , <b>2019</b> , 7, 220-228	1.1	1
15	Perioperative management of biologic agents in Crohn's disease. <i>Seminars in Colon and Rectal Surgery</i> , <b>2022</b> , 33, 100865	0.3	
14	Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management <i>Psoriasis: Targets and Therapy</i> , <b>2022</b> , 12, 1-14	2.4	1
13	Crohn's disease in total knee arthroplasty patients correlates with increased rates of 90-day and overall postoperative complications and readmissions <i>Knee</i> , <b>2022</b> , 34, 238-245	2.6	О

12	Retrospective Study of Surgical Outcomes in 60 Patients with Crohn Disease from a Single Center in Poland <i>Medical Science Monitor</i> , <b>2022</b> , 28, e934463	3.2	
11	Surgical Management of Crohn Disease. Gastroenterology Clinics of North America, 2022,	4.4	
10	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. <i>Intestinal Research</i> ,	4.1	1
9	Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts. 1-5		
8	Perioperative Management of Ulcerative Colitis: A Systematic Review. Publish Ahead of Print,		
7	Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. <b>2022</b> , 101, e30590		O
6	Perioperative optimization of Crohn's disease.		O
6 5	Perioperative optimization of Crohn's disease.  Korean clinical practice guidelines on biologics for moderate to severe Crohn® disease.		0
5	Korean clinical practice guidelines on biologics for moderate to severe Crohn⊠ disease.		O
5	Korean clinical practice guidelines on biologics for moderate to severe Crohn disease.  Treatment of Crohn's disease. 2022, 181,  Safety Analysis of Preoperative Anti-TNF-Therapy in Pediatric IBD After Intestinal Resection: A		0